Kawamura, Hitomi
Sakurai, Hidehiko
Sakamoto, Takuya
Arai, Hiroto
Naoi, Kazuyuki
Tsukui, Rie
Iwamoto, Sanju
Aizawa, Madoka
Kishimoto, Keiko
Funding for this research was provided by:
Pfizer Health Research Foundation (21-Y-03, 21-Y-03, 21-Y-03)
Article History
Received: 6 January 2025
Accepted: 12 June 2025
First Online: 3 July 2025
Declarations
:
: The study adhered to the principles outlined in the Declaration of Helsinki and received approval from the Showa Medical University (Tokyo, Japan) Research Ethics Review Board (approval number: 22–016-A). At the beginning of the online screen, a document was displayed that contained the details of the research that had been approved by the ethics review board. This document stated that participation in the study was voluntary, that participants could withdraw from the study at any time, and that there would be no disadvantage to participants who withdrew. After reading this document, consent was obtained. The consent was obtained by pressing the ‘I agree to participate in the study’ button on the online screen. Only those who pressed this button could proceed to the questionnaire screen. All participants in this study provided consent in the way described. Informed consent to participate was obtained from all participants.
: Not applicable.
: The authors declare no competing interests.